Value-Based Pricing: Do Not Throw Away the Baby with the Bath Water Mattias Neyt Commentary 03 October 2017 Pages: 1 - 3
Value-Based Pricing: L’Enfant Terrible? Sarah GarnerAndrew RintoulSuzanne R. Hill Reply Open access 21 December 2017 Pages: 5 - 6
Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment Jaclyn BecaDon HusereauJeffrey S. Hoch Current Opinion 06 November 2017 Pages: 7 - 15
Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices: An Updated Review Alisha MonnetteYichen ZhangLizheng Shi Review Article 11 September 2017 Pages: 17 - 27
Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Hazel SquiresAbdullah PandorLynda Wyld Review Article 02 August 2017 Pages: 29 - 38
Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal Irina A. TikhonovaTracey Jones-HughesMartin Hoyle Review Article 15 September 2017 Pages: 39 - 49
The Use of Decision–Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal Emma McManusTracey SachNick Levell Systematic Review 01 September 2017 Pages: 51 - 66
Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis Samuel HerzogMarian ShanahanRachael L. Morton Systematic Review 02 September 2017 Pages: 67 - 78
Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework Natalie CarvalhoMark JitRaymond C. W. Hutubessy Systematic Review Open access 13 September 2017 Pages: 79 - 90
Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy Amir AnsaripourCarin A. Uyl-de GrootW. Ken Redekop Original Research Article Open access 09 August 2017 Pages: 91 - 103
Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research Thea van AsseltBram RamaekersTalitha Feenstra Original Research Article Open access 20 September 2017 Pages: 105 - 113
Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease Usha G. MallyaSusan H. BoklageC. Daniel Mullins Original Research Article Open access 27 November 2017 Pages: 115 - 126